{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T01:28:10Z","timestamp":1794533290183,"version":"4.9.1"},"reference-count":257,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Jiangxi Province-Youth Fund Project","award":["[20212BAB216045 and 20224BAB216013]"],"award-info":[{"award-number":["[20212BAB216045 and 20224BAB216013]"]}]},{"name":"the National Natural Science Foundation of China-Regional Program","award":["[82360083]"],"award-info":[{"award-number":["[82360083]"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-025-02600-y","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T05:06:25Z","timestamp":1748063185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Lipoprotein(a) and panvascular disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Ruiyan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"2600_CR1","doi-asserted-by":"publisher","first-page":"899","DOI":"10.33963\/KP.15034","volume":"77","author":"P Musia\u0142ek","year":"2019","unstructured":"Musia\u0142ek P, Montauk L, Saugnet A, Micari A, Hopkins LN. The cardio-vascular future of panvascular medicine: the basics. Kardiol Pol. 2019;77:899\u2013901. https:\/\/doi.org\/10.33963\/KP.15034.","journal-title":"Kardiol Pol"},{"key":"2600_CR2","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.scib.2023.07.032","volume":"68","author":"Y Hu","year":"2023","unstructured":"Hu Y, Zhao Y, Li P, Lu H, Li H, Ge J. Hypoxia and panvascular diseases: exploring the role of hypoxia-inducible factors in vascular smooth muscle cells under panvascular pathologies. Sci Bull. 2023;68:1954\u201374. https:\/\/doi.org\/10.1016\/j.scib.2023.07.032.","journal-title":"Sci Bull"},{"key":"2600_CR3","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361.","journal-title":"Eur Heart J"},{"key":"2600_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","volume":"7","author":"F Duarte Lau","year":"2022","unstructured":"Duarte Lau F, Giugliano RP. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. JAMA Cardiol. 2022;7:760. https:\/\/doi.org\/10.1001\/jamacardio.2022.0987.","journal-title":"JAMA Cardiol"},{"key":"2600_CR5","doi-asserted-by":"publisher","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42. https:\/\/doi.org\/10.1161\/ATV.0000000000000147","DOI":"10.1161\/ATV.0000000000000147"},{"key":"2600_CR6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/phar.2851","volume":"43","author":"IS Alhomoud","year":"2023","unstructured":"Alhomoud IS, Talasaz A, Mehta A, et al. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies. Pharmacother J Hum Pharmacol Drug Ther. 2023;43:1051\u201363. https:\/\/doi.org\/10.1002\/phar.2851.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"2600_CR7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s41586-024-07387-z","volume":"629","author":"N Diaz","year":"2024","unstructured":"Diaz N, Perez C, Escribano AM, et al. Discovery of potent small-molecule inhibitors of lipoprotein(a) formation. Nature. 2024;629:945\u201350. https:\/\/doi.org\/10.1038\/s41586-024-07387-z.","journal-title":"Nature"},{"key":"2600_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024870","volume":"11","author":"OH Obisesan","year":"2022","unstructured":"Obisesan OH, Kou M, Wang FM, et al. Lipoprotein(a) and Subclinical Vascular and Valvular Calcification on Cardiac Computed Tomography: The Atherosclerosis Risk in Communities Study. J Am Heart Assoc. 2022;11: e024870. https:\/\/doi.org\/10.1161\/JAHA.121.024870.","journal-title":"J Am Heart Assoc"},{"key":"2600_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154960","volume":"127","author":"J Peng","year":"2022","unstructured":"Peng J, Liu M-M, Liu H-H, Xu R-X, Zhu C-G, Guo Y-L, et al. Lipoprotein (a)-mediated vascular calcification: Population-based and in vitro studies. Metabolism. 2022;127: 154960. https:\/\/doi.org\/10.1016\/j.metabol.2021.154960.","journal-title":"Metabolism"},{"key":"2600_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.117405","volume":"388","author":"Y Qiu","year":"2024","unstructured":"Qiu Y, Hao W, Guo Y, et al. The association of lipoprotein (a) with coronary artery calcification: A systematic review and meta-analysis. Atherosclerosis. 2024;388: 117405. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117405.","journal-title":"Atherosclerosis"},{"key":"2600_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.clinbiochem.2003.12.007","volume":"37","author":"MB Boffa","year":"2004","unstructured":"Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem. 2004;37:333\u201343. https:\/\/doi.org\/10.1016\/j.clinbiochem.2003.12.007.","journal-title":"Clin Biochem"},{"key":"2600_CR12","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.7150\/thno.71813","volume":"12","author":"K Phua","year":"2022","unstructured":"Phua K, Chew NW, Kong WK, Tan R-S, Ye L, Poh K-K. The mechanistic pathways of oxidative stress in aortic stenosis and clinical implications. Theranostics. 2022;12:5189\u2013203. https:\/\/doi.org\/10.7150\/thno.71813.","journal-title":"Theranostics"},{"key":"2600_CR13","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.3390\/cells11172663","volume":"11","author":"DM Tanase","year":"2022","unstructured":"Tanase DM, Valasciuc E, Gosav EM, et al. Contribution of oxidative stress (OS) in calcific aortic valve disease (CAVD): From pathophysiology to therapeutic targets. Cells. 2022;11:2663. https:\/\/doi.org\/10.3390\/cells11172663.","journal-title":"Cells"},{"key":"2600_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1055\/s-0038-1645041","volume":"63","author":"LA Miles","year":"1990","unstructured":"Miles LA, Plow EF. Lp(a): An interloper into the fibrinolytic system? Thromb Haemost. 1990;63:331\u20135.","journal-title":"Thromb Haemost"},{"key":"2600_CR15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/clc.4960270503","volume":"27","author":"A Deb","year":"2004","unstructured":"Deb A, Caplice NM. Lipoprotein(a): New insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol. 2004;27:258\u201364. https:\/\/doi.org\/10.1002\/clc.4960270503.","journal-title":"Clin Cardiol"},{"key":"2600_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11883-005-0052-y","volume":"7","author":"ML Koschinsky","year":"2005","unstructured":"Koschinsky ML. Lipoprotein(a) and atherosclerosis: New perspectives on the mechanism of action of an enigmatic lipoprotein. Curr Atheroscler Rep. 2005;7:389\u201395. https:\/\/doi.org\/10.1007\/s11883-005-0052-y.","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"2600_CR17","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1002\/jcp.26050","volume":"233","author":"G Ferretti","year":"2018","unstructured":"Ferretti G, Bacchetti T, Johnston TP, Banach M, Pirro M, Sahebkar A. Lipoprotein(a): A missing culprit in the management of athero-thrombosis? J Cell Physiol. 2018;233(4):2966\u201381. https:\/\/doi.org\/10.1002\/jcp.26050.","journal-title":"J Cell Physiol"},{"issue":"1","key":"2600_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","volume":"67","author":"PR Kamstrup","year":"2021","unstructured":"Kamstrup PR. Lipoprotein(a) and Cardiovascular Disease. Clin Chem. 2021;67(1):154\u201366. https:\/\/doi.org\/10.1093\/clinchem\/hvaa247.","journal-title":"Clin Chem"},{"key":"2600_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejim.2023.10.013","volume":"120","author":"F Gomez-Delgado","year":"2024","unstructured":"Gomez-Delgado F, Raya-Cruz M, Katsiki N, Delgado-Lista J, Perez-Martinez P. Residual cardiovascular risk: When should we treat it? Eur J Intern Med. 2024;120:17\u201324. https:\/\/doi.org\/10.1016\/j.ejim.2023.10.013.","journal-title":"Eur J Intern Med"},{"key":"2600_CR20","doi-asserted-by":"publisher","first-page":"1392859","DOI":"10.3389\/fendo.2024.1392859","volume":"15","author":"Z Wang","year":"2024","unstructured":"Wang Z, Tang J, Shi Q, Fang L, Liu N, Zhang J. Synergistic effect of lipoprotein(a) and high-sensitivity C-reactive protein on the risk of all-cause and cardiovascular death in patients with acute myocardial infarction: a large prospective cohort study. Front Endocrinol (Lausanne). 2024;15:1392859. https:\/\/doi.org\/10.3389\/fendo.2024.1392859.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2600_CR21","doi-asserted-by":"publisher","unstructured":"Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb J Vasc Biol. 1992;12: 1214\u20131226. https:\/\/doi.org\/10.1161\/01.ATV.12.10.1214","DOI":"10.1161\/01.ATV.12.10.1214"},{"key":"2600_CR22","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","volume":"361","author":"R Clarke","year":"2009","unstructured":"Clarke R, Peden JF, Hopewell JC, et al. Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease. N Engl J Med. 2009;361:2518\u201328. https:\/\/doi.org\/10.1056\/NEJMoa0902604.","journal-title":"N Engl J Med"},{"key":"2600_CR23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","volume":"3","author":"S Burgess","year":"2018","unstructured":"Burgess S, Ference BA, Staley JR, et al. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: A mendelian randomization analysis. JAMA Cardiol. 2018;3:619. https:\/\/doi.org\/10.1001\/jamacardio.2018.1470.","journal-title":"JAMA Cardiol"},{"key":"2600_CR24","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1161\/STROKEAHA.119.026872","volume":"50","author":"Y Pan","year":"2019","unstructured":"Pan Y, Li H, Wang Y, Meng X, Wang Y. Causal effect of lp(a) [lipoprotein(a)] level on ischemic stroke and alzheimer disease: A mendelian randomization study. Stroke. 2019;50:3532\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.119.026872.","journal-title":"Stroke"},{"key":"2600_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155347","volume":"137","author":"SC Larsson","year":"2022","unstructured":"Larsson SC, Wang L, Li X, Jiang F, Chen X, Mantzoros CS. Circulating lipoprotein(a) levels and health outcomes: Phenome-wide Mendelian randomization and disease-trajectory analyses. Metabolism. 2022;137: 155347. https:\/\/doi.org\/10.1016\/j.metabol.2022.155347.","journal-title":"Metabolism"},{"key":"2600_CR26","doi-asserted-by":"publisher","unstructured":"Berg K. A NEW SERUM TYPE SYSTEM IN MAN-THE Lp SYSTEM. https:\/\/doi.org\/10.1111\/j.1699-0463.1963.tb01808.x","DOI":"10.1111\/j.1699-0463.1963.tb01808.x"},{"key":"2600_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/330132a0","volume":"330","author":"JW McLean","year":"1987","unstructured":"McLean JW, Tomlinson JE, Kuang W-J, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132\u20137. https:\/\/doi.org\/10.1038\/330132a0.","journal-title":"Nature"},{"key":"2600_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105812","volume":"173","author":"M Ruscica","year":"2021","unstructured":"Ruscica M, Sirtori CR, Corsini A, Watts GF, Sahebkar A. Lipoprotein(a): Knowns, unknowns and uncertainties. Pharmacol Res. 2021;173: 105812. https:\/\/doi.org\/10.1016\/j.phrs.2021.105812.","journal-title":"Pharmacol Res"},{"issue":"6","key":"2600_CR29","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0022-2275(20)32028-9","volume":"41","author":"PG Frank","year":"2000","unstructured":"Frank PG, Marcel YL. Apolipoprotein A-I: structure-function relationships. J Lipid Res. 2000;41(6):853\u201372.","journal-title":"J Lipid Res"},{"key":"2600_CR30","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","volume":"55","author":"S Erqou","year":"2010","unstructured":"Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) Isoforms and the Risk of Vascular Disease. J Am Coll Cardiol. 2010;55:2160\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2009.10.080.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2600_CR31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/BF00201550","volume":"86","author":"C Sandholzer","year":"1991","unstructured":"Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86(6):607\u201314. https:\/\/doi.org\/10.1007\/BF00201550.","journal-title":"Hum Genet"},{"key":"2600_CR32","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A Test in Context: Lipoprotein(a). J Am Coll Cardiol. 2017;69:692\u2013711. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.042.","journal-title":"J Am Coll Cardiol"},{"key":"2600_CR33","doi-asserted-by":"publisher","unstructured":"Mehta A, Jain, Saeed A, et al. Lipoprotein(a) and ethnicities. Atherosclerosis. 2022;349:42\u201352. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.005","DOI":"10.1016\/j.atherosclerosis.2022.04.005"},{"key":"2600_CR34","doi-asserted-by":"publisher","unstructured":"Guyton JR, Dahlen GH, Patsch W, Kautz JA, Gotto AM. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arterioscler Off J Am Heart Assoc Inc. 1985;5:265\u2013272. https:\/\/doi.org\/10.1161\/01.ATV.5.3.265","DOI":"10.1161\/01.ATV.5.3.265"},{"key":"2600_CR35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.metabol.2004.10.001","volume":"54","author":"JL Jenner","year":"2005","unstructured":"Jenner JL, Seman LJ, Millar JS, et al. The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings. Metabolism. 2005;54:361\u20139. https:\/\/doi.org\/10.1016\/j.metabol.2004.10.001.","journal-title":"Metabolism"},{"key":"2600_CR36","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","volume":"57","author":"K Schmidt","year":"2016","unstructured":"Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57:1339\u201359. https:\/\/doi.org\/10.1194\/jlr.R067314.","journal-title":"J Lipid Res"},{"key":"2600_CR37","doi-asserted-by":"publisher","first-page":"030006052412641","DOI":"10.1177\/03000605241264182","volume":"52","author":"CE Kosmas","year":"2024","unstructured":"Kosmas CE, Bousvarou MD, Papakonstantinou EJ, Zoumi E-A, Rallidis LS. Lipoprotein (a) and cerebrovascular disease. J Int Med Res. 2024;52:03000605241264182. https:\/\/doi.org\/10.1177\/03000605241264182.","journal-title":"J Int Med Res"},{"key":"2600_CR38","doi-asserted-by":"publisher","unstructured":"Miller YI, Choi S-H, Wiesner P, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Hazen S, McIntyre TM, editors. Circ Res. 2011;108: 235\u2013248. https:\/\/doi.org\/10.1161\/CIRCRESAHA.110.223875","DOI":"10.1161\/CIRCRESAHA.110.223875"},{"key":"2600_CR39","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","volume":"49","author":"C Bergmark","year":"2008","unstructured":"Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49:2230\u20139. https:\/\/doi.org\/10.1194\/jlr.M800174-JLR200.","journal-title":"J Lipid Res"},{"key":"2600_CR40","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2022.04.004","volume":"349","author":"KE Dzobo","year":"2022","unstructured":"Dzobo KE, Kraaijenhof JM, Stroes ESG, Nurmohamed NS, Kroon J. Lipoprotein(a): An underestimated inflammatory mastermind. Atherosclerosis. 2022;349:101\u20139. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.004.","journal-title":"Atherosclerosis"},{"key":"2600_CR41","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","volume":"66","author":"R Capoulade","year":"2015","unstructured":"Capoulade R, Chan KL, Yeang C, et al. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. J Am Coll Cardiol. 2015;66:1236\u201346. https:\/\/doi.org\/10.1016\/j.jacc.2015.07.020.","journal-title":"J Am Coll Cardiol"},{"key":"2600_CR42","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","volume":"349","author":"ML Koschinsky","year":"2022","unstructured":"Koschinsky ML, Boffa MB. Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology. Atherosclerosis. 2022;349:92\u2013100. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.001.","journal-title":"Atherosclerosis"},{"key":"2600_CR43","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3390\/molecules28030969","volume":"28","author":"S Lampsas","year":"2023","unstructured":"Lampsas S, Xenou M, Oikonomou E, et al. Lipoprotein(a) in atherosclerotic diseases: From pathophysiology to diagnosis and treatment. Molecules. 2023;28:969. https:\/\/doi.org\/10.3390\/molecules28030969.","journal-title":"Molecules"},{"key":"2600_CR44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbrc.2012.05.086","volume":"423","author":"M Iwabayashi","year":"2012","unstructured":"Iwabayashi M, Taniyama Y, Sanada F, et al. Inhibition of lp(a)-induced functional impairment of endothelial cells and endothelial progenitor cells by hepatocyte growth factor. Biochem Biophys Res Commun. 2012;423:79\u201384. https:\/\/doi.org\/10.1016\/j.bbrc.2012.05.086.","journal-title":"Biochem Biophys Res Commun"},{"key":"2600_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11789-019-00100-9","volume":"14","author":"KP Mellwig","year":"2019","unstructured":"Mellwig KP, Vogt A. Lipoprotein(a). Clin Res Cardiol Suppl. 2019;14:1\u20134. https:\/\/doi.org\/10.1007\/s11789-019-00100-9.","journal-title":"Clin Res Cardiol Suppl"},{"key":"2600_CR46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/biom12010026","volume":"12","author":"S Ugov\u0161ek","year":"2021","unstructured":"Ugov\u0161ek S, \u0160ebe\u0161tjen M. Lipoprotein(a)\u2014the crossroads of atherosclerosis, atherothrombosis and inflammation. Biomolecules. 2021;12:26. https:\/\/doi.org\/10.3390\/biom12010026.","journal-title":"Biomolecules"},{"key":"2600_CR47","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1161\/ATVBAHA.112.251306","volume":"32","author":"JD Spence","year":"2012","unstructured":"Spence JD, Koschinsky M. Mechanisms of Lipoprotein(a) Pathogenicity: Prothrombotic, Proatherosclerotic, or Both? Arterioscler Thromb Vasc Biol. 2012;32:1550\u20131. https:\/\/doi.org\/10.1161\/ATVBAHA.112.251306.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2600_CR48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s11883-003-0081-3","volume":"5","author":"AM Scanu","year":"2003","unstructured":"Scanu AM. Lipoprotein(a) and the atherothrombotic process: Mechanistic insights and clinical implications. Curr Atheroscler Rep. 2003;5:106\u201313. https:\/\/doi.org\/10.1007\/s11883-003-0081-3.","journal-title":"Curr Atheroscler Rep"},{"key":"2600_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2018.07.002","volume":"169","author":"R Romagnuolo","year":"2018","unstructured":"Romagnuolo R, DeMarco K, Scipione CA, Boffa MB, Koschinsky ML. Apolipoprotein(a) inhibits the conversion of glu-plasminogen to lys-plasminogen on the surface of vascular endothelial and smooth muscle cells. Thromb Res. 2018;169:1\u20137. https:\/\/doi.org\/10.1016\/j.thromres.2018.07.002.","journal-title":"Thromb Res"},{"key":"2600_CR50","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1590\/S0100-879X1997001100002","volume":"30","author":"E Angl\u00e9s-Cano","year":"1997","unstructured":"Angl\u00e9s-Cano E. Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process. Braz J Med Biol Res. 1997;30:1271\u201380. https:\/\/doi.org\/10.1590\/S0100-879X1997001100002.","journal-title":"Braz J Med Biol Res"},{"key":"2600_CR51","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1194\/jlr.R060582","volume":"57","author":"MB Boffa","year":"2016","unstructured":"Boffa MB, Koschinsky ML. Lipoprotein (a): Truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res. 2016;57:745\u201357. https:\/\/doi.org\/10.1194\/jlr.R060582.","journal-title":"J Lipid Res"},{"key":"2600_CR52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/330113a0","volume":"330","author":"MS Brown","year":"1987","unstructured":"Brown MS, Goldstein JL. Teaching old dogmas new tricks. Nature. 1987;330:113\u20134. https:\/\/doi.org\/10.1038\/330113a0.","journal-title":"Nature"},{"key":"2600_CR53","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1161\/01.RES.78.4.615","volume":"78","author":"LB Nielsen","year":"1996","unstructured":"Nielsen LB, Stender S, Kjeldsen K, Nordestgaard BG. Specific Accumulation of Lipoprotein(a) in Balloon-Injured Rabbit Aorta In Vivo. Circ Res. 1996;78:615\u201326. https:\/\/doi.org\/10.1161\/01.RES.78.4.615.","journal-title":"Circ Res"},{"key":"2600_CR54","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1177\/002215549704500408","volume":"45","author":"Y Yano","year":"1997","unstructured":"Yano Y, Shimokawa K, Okada Y, Noma A. Immunolocalization of lipoprotein(a) in wounded tissues. J Histochem Cytochem. 1997;45:559\u201368. https:\/\/doi.org\/10.1177\/002215549704500408.","journal-title":"J Histochem Cytochem"},{"key":"2600_CR55","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12944-022-01720-z","volume":"21","author":"S Ruder","year":"2022","unstructured":"Ruder S, Mansfield B, Immelman AR, et al. Lp(a), oxidized phospholipids and oxidation-specific epitopes are increased in subjects with keloid formation. Lipids Health Dis. 2022;21:113. https:\/\/doi.org\/10.1186\/s12944-022-01720-z.","journal-title":"Lipids Health Dis"},{"key":"2600_CR56","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","volume":"63","author":"PR Kamstrup","year":"2014","unstructured":"Kamstrup PR, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63:470\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2013.09.038.","journal-title":"J Am Coll Cardiol"},{"key":"2600_CR57","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1002\/pro.5560031222","volume":"3","author":"LE Donate","year":"1994","unstructured":"Donate LE, Srinivasan N, Sowdhamini R, Gherardi E, Blundell TL, Aparicio S. Molecular evolution and domain structure of plasminogen-related growth factors (HGF\/SF and HGF1\/MSP). Protein Sci. 1994;3:2378\u201394. https:\/\/doi.org\/10.1002\/pro.5560031222.","journal-title":"Protein Sci"},{"issue":"7","key":"2600_CR58","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001172","volume":"148","author":"SM Grundy","year":"2023","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. Correction to: 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2023;148(7): e5. https:\/\/doi.org\/10.1161\/CIR.0000000000001172.","journal-title":"Circulation"},{"key":"2600_CR59","doi-asserted-by":"publisher","unstructured":"Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412\u2013423. https:\/\/doi.org\/10.1001\/jama.2009.1063","DOI":"10.1001\/jama.2009.1063"},{"issue":"1","key":"2600_CR60","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1186\/s12889-024-19443-4","volume":"24","author":"Z Wang","year":"2024","unstructured":"Wang Z, Yan X, Fang L, Tang J, Zhang J. Association between lipoprotein(a), fibrinogen and their combination with all-cause, cardiovascular disease and cancer-related mortality: findings from the NHANES. BMC Public Health. 2024;24(1):1927. https:\/\/doi.org\/10.1186\/s12889-024-19443-4.","journal-title":"BMC Public Health"},{"key":"2600_CR61","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","volume":"102","author":"J Danesh","year":"2000","unstructured":"Danesh J, Collins R, Peto R. Lipoprotein(a) and Coronary Heart Disease: Meta-Analysis of Prospective Studies. Circulation. 2000;102:1082\u20135. https:\/\/doi.org\/10.1161\/01.CIR.102.10.1082.","journal-title":"Circulation"},{"issue":"1","key":"2600_CR62","doi-asserted-by":"publisher","first-page":"2454975","DOI":"10.1080\/07853890.2025.2454975","volume":"57","author":"Z Wang","year":"2025","unstructured":"Wang Z, Tang J, Shi Q, Fang L, Liu N, Zhang J. Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study. Ann Med. 2025;57(1):2454975. https:\/\/doi.org\/10.1080\/07853890.2025.2454975.","journal-title":"Ann Med"},{"key":"2600_CR63","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J. 2010;31:2844\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehq386.","journal-title":"Eur Heart J"},{"key":"2600_CR64","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","volume":"117","author":"PR Kamstrup","year":"2008","unstructured":"Kamstrup PR, Benn M, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study. Circulation. 2008;117:176\u201384. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.715698.","journal-title":"Circulation"},{"key":"2600_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117220","volume":"540","author":"Z Wang","year":"2023","unstructured":"Wang Z, Xiao S, Liu N. Association of lipoprotein(a) with coronary severity in patients with new-onset acute myocardial infarction: A large cross-sectional study. Clin Chim Acta. 2023;540: 117220. https:\/\/doi.org\/10.1016\/j.cca.2023.117220.","journal-title":"Clin Chim Acta"},{"key":"2600_CR66","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331. https:\/\/doi.org\/10.1001\/jama.2009.801.","journal-title":"JAMA"},{"key":"2600_CR67","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","volume":"4","author":"PR Kamstrup","year":"2016","unstructured":"Kamstrup PR, Nordestgaard BG. Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population. JACC Heart Fail. 2016;4:78\u201387. https:\/\/doi.org\/10.1016\/j.jchf.2015.08.006.","journal-title":"JACC Heart Fail"},{"key":"2600_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117226","volume":"540","author":"ZW Wang","year":"2023","unstructured":"Wang ZW, Xiao SJ, Liu NF. Association of lipoprotein(a) with left ventricular hypertrophy in patients with new-onset acute myocardial infarction: A large cross-sectional study. Clin Chim Acta. 2023;540: 117226. https:\/\/doi.org\/10.1016\/j.cca.2023.117226.","journal-title":"Clin Chim Acta"},{"key":"2600_CR69","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40842-016-0024-x","volume":"2","author":"R Saeedi","year":"2016","unstructured":"Saeedi R, Frohlich J. Lipoprotein (a), an independent cardiovascular risk marker. Clin Diabetes Endocrinol. 2016;2:7. https:\/\/doi.org\/10.1186\/s40842-016-0024-x.","journal-title":"Clin Diabetes Endocrinol"},{"key":"2600_CR70","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1093\/eurheartj\/eht053","volume":"34","author":"KM Kostner","year":"2013","unstructured":"Kostner KM, Marz W, Kostner GM. When should we measure lipoprotein (a)? Eur Heart J. 2013;34:3268\u201376. https:\/\/doi.org\/10.1093\/eurheartj\/eht053.","journal-title":"Eur Heart J"},{"key":"2600_CR71","doi-asserted-by":"publisher","unstructured":"Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368: 503\u2013512]. https:\/\/doi.org\/10.1056\/NEJMoa1109034","DOI":"10.1056\/NEJMoa1109034"},{"key":"2600_CR72","doi-asserted-by":"publisher","unstructured":"CARDIoGRAMplusC4D Consortium, Deloukas P, Kanoni S, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet. 2013;45(1):25\u201333. https:\/\/doi.org\/10.1038\/ng.2480","DOI":"10.1038\/ng.2480"},{"key":"2600_CR73","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","volume":"41","author":"AP Patel","year":"2021","unstructured":"Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: New insights from a large national biobank. Arterioscler Thromb Vasc Biol. 2021;41:465\u201374. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315291.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10459","key":"2600_CR74","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","volume":"404","author":"BG Nordestgaard","year":"2024","unstructured":"Nordestgaard BG, Langsted A. Lipoprotein(a) and cardiovascular disease. Lancet. 2024;404(10459):1255\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(24)01308-4.","journal-title":"Lancet"},{"key":"2600_CR75","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.1074\/jbc.M309705200","volume":"279","author":"M Pellegrino","year":"2004","unstructured":"Pellegrino M, Furmaniak-Kazmierczak E, LeBlanc JC, et al. The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J Biol Chem. 2004;279:6526\u201333. https:\/\/doi.org\/10.1074\/jbc.M309705200.","journal-title":"J Biol Chem"},{"key":"2600_CR76","doi-asserted-by":"publisher","first-page":"30503","DOI":"10.1074\/jbc.M802648200","volume":"283","author":"T Cho","year":"2008","unstructured":"Cho T, Jung Y, Koschinsky ML. Apolipoprotein(a), through its strong lysine-binding site in KIV10, mediates increased endothelial cell contraction and permeability via a rho\/rho kinase\/MYPT1-dependent pathway. J Biol Chem. 2008;283:30503\u201312. https:\/\/doi.org\/10.1074\/jbc.M802648200.","journal-title":"J Biol Chem"},{"key":"2600_CR77","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1096\/fasebj.12.15.1765","volume":"12","author":"S Allen","year":"1998","unstructured":"Allen S, Khan S, Tam S-P, Koschinsky M, Taylor P, Yacoub M. Expression of adhesion molecules by lp(a): A potential novel mechanism for its atherogenicity. FASEB J. 1998;12:1765\u201376. https:\/\/doi.org\/10.1096\/fasebj.12.15.1765.","journal-title":"FASEB J"},{"key":"2600_CR78","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1161\/01.ATV.15.9.1492","volume":"15","author":"LB Nielsen","year":"1995","unstructured":"Nielsen LB, Nordestgaard BG, Stender S, Niendorf A, Kjeldsen K. Transfer of lipoprotein(a) and LDL into aortic intima in normal and in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol. 1995;15:1492\u2013502. https:\/\/doi.org\/10.1161\/01.ATV.15.9.1492.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2600_CR79","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0021-9150(99)00064-7","volume":"143","author":"LB Nielsen","year":"1999","unstructured":"Nielsen LB. Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: Insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis. 1999;143:229\u201343. https:\/\/doi.org\/10.1016\/S0021-9150(99)00064-7.","journal-title":"Atherosclerosis"},{"key":"2600_CR80","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1161\/01.ATV.17.6.1011","volume":"17","author":"E Hurt-Camejo","year":"1997","unstructured":"Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, Camejo G. Cellular consequences of the association of ApoB lipoproteins with proteoglycans: Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol. 1997;17:1011\u20137. https:\/\/doi.org\/10.1161\/01.ATV.17.6.1011.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2600_CR81","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1161\/01.ATV.19.5.1162","volume":"19","author":"U Lundstam","year":"1999","unstructured":"Lundstam U, Hurt-Camejo E, Olsson G, Sartipy P, Camejo G, Wiklund O. Proteoglycans contribution to association of lp(a) and LDL with smooth muscle cell extracellular matrix. Arterioscler Thromb Vasc Biol. 1999;19:1162\u20137. https:\/\/doi.org\/10.1161\/01.ATV.19.5.1162.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2600_CR82","doi-asserted-by":"publisher","first-page":"23856","DOI":"10.1074\/jbc.273.37.23856","volume":"273","author":"O Klezovitch","year":"1998","unstructured":"Klezovitch O, Edelstein C, Zhu L, Scanu AM. Apolipoprotein(a) binds via its C-terminal domain to the protein core of the proteoglycan decorin. J Biol Chem. 1998;273:23856\u201365. https:\/\/doi.org\/10.1074\/jbc.273.37.23856.","journal-title":"J Biol Chem"},{"key":"2600_CR83","doi-asserted-by":"publisher","unstructured":"Hughes SD, Lou XJ, Ighani S, et al. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest. 1997;100: 1493\u20131500. https:\/\/doi.org\/10.1172\/JCI119671","DOI":"10.1172\/JCI119671"},{"key":"2600_CR84","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1182\/blood.V89.12.4290","volume":"89","author":"AA Higazi","year":"1997","unstructured":"Higazi AA, Lavi E, Bdeir K, et al. Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. Blood. 1997;89:4290\u20138.","journal-title":"Blood"},{"issue":"6","key":"2600_CR85","first-page":"2007","volume":"94","author":"K Bdeir","year":"1999","unstructured":"Bdeir K, Cane W, Canziani G, et al. Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood. 1999;94(6):2007\u201319.","journal-title":"Blood"},{"key":"2600_CR86","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1194\/jlr.M040733","volume":"54","author":"G Leibundgut","year":"2013","unstructured":"Leibundgut G, Scipione C, Yin H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res. 2013;54:2815\u201330. https:\/\/doi.org\/10.1194\/jlr.M040733.","journal-title":"J Lipid Res"},{"key":"2600_CR87","doi-asserted-by":"publisher","first-page":"C7","DOI":"10.1016\/j.jacc.2005.09.068","volume":"47","author":"E Falk","year":"2006","unstructured":"Falk E. Pathogenesis of Atherosclerosis. J Am Coll Cardiol. 2006;47:C7-12. https:\/\/doi.org\/10.1016\/j.jacc.2005.09.068.","journal-title":"J Am Coll Cardiol"},{"key":"2600_CR88","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1126\/science.8503012","volume":"260","author":"DJ Grainger","year":"1993","unstructured":"Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655\u20138. https:\/\/doi.org\/10.1126\/science.8503012.","journal-title":"Science"},{"key":"2600_CR89","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cmet.2010.09.010","volume":"12","author":"TA Seimon","year":"2010","unstructured":"Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010;12:467\u201382. https:\/\/doi.org\/10.1016\/j.cmet.2010.09.010.","journal-title":"Cell Metab"},{"key":"2600_CR90","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1161\/CIRCULATIONAHA.120.052023","volume":"144","author":"F Fasolo","year":"2021","unstructured":"Fasolo F, Jin H, Winski G, et al. Long noncoding RNA MIAT controls advanced atherosclerotic lesion formation and plaque destabilization. Circulation. 2021;144:1567\u201383. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052023.","journal-title":"Circulation"},{"key":"2600_CR91","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.01.020","volume":"246","author":"G Niccoli","year":"2016","unstructured":"Niccoli G, Cin D, Scalone G, et al. Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. Atherosclerosis. 2016;246:214\u201320. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.01.020.","journal-title":"Atherosclerosis"},{"key":"2600_CR92","doi-asserted-by":"publisher","unstructured":"Samah N, Ugusman A, Hamid AA, Sulaiman N, Aminuddin A. Role of matrix metalloproteinase-2 in the development of atherosclerosis among patients with coronary artery disease. Dalmarco E, editor. Mediators Inflamm. 2023;2023: 1\u201316. https:\/\/doi.org\/10.1155\/2023\/9715114","DOI":"10.1155\/2023\/9715114"},{"issue":"2","key":"2600_CR93","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3892\/ijmm.2011.693","volume":"28","author":"D W\u00e5gs\u00e4ter","year":"2011","unstructured":"W\u00e5gs\u00e4ter D, Zhu C, Bj\u00f6rkegren J, Skogsberg J, Eriksson P. MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr(-\/-)Apob(100\/100) mouse. Int J Mol Med. 2011;28(2):247\u201353. https:\/\/doi.org\/10.3892\/ijmm.2011.693.","journal-title":"Int J Mol Med"},{"key":"2600_CR94","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11883-024-01215-5","volume":"26","author":"T Qin","year":"2024","unstructured":"Qin T, Ma T-Y, Huang K, Lu S-J, Zhong J-H, Li J-J. Lipoprotein (a)-related inflammatory imbalance: A novel horizon for the development of atherosclerosis. Curr Atheroscler Rep. 2024;26:383\u201394. https:\/\/doi.org\/10.1007\/s11883-024-01215-5.","journal-title":"Curr Atheroscler Rep"},{"key":"2600_CR95","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.clinbiochem.2004.09.011","volume":"38","author":"D Bilgen","year":"2005","unstructured":"Bilgen D, S\u00f6nmez H, Ekmek\u00e7i H, et al. The relationship of TFPI, lp(a), and oxidized LDL antibody levels in patients with coronary artery disease. Clin Biochem. 2005;38:92\u20136. https:\/\/doi.org\/10.1016\/j.clinbiochem.2004.09.011.","journal-title":"Clin Biochem"},{"key":"2600_CR96","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41569-023-00947-2","volume":"21","author":"HS Bhatia","year":"2024","unstructured":"Bhatia HS, Becker RC, Leibundgut G, et al. Lipoprotein(a), platelet function and cardiovascular disease. Nat Rev Cardiol. 2024;21:299\u2013311. https:\/\/doi.org\/10.1038\/s41569-023-00947-2.","journal-title":"Nat Rev Cardiol"},{"key":"2600_CR97","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","volume":"134","author":"FM Van Der Valk","year":"2016","unstructured":"Van Der Valk FM, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134:611\u201324. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.020838.","journal-title":"Circulation"},{"key":"2600_CR98","doi-asserted-by":"publisher","unstructured":"Jones BW, Heldwein KA, Means TK, Saukkonen JJ, Fenton MJ. Differential roles of Toll-like receptors in the elicitation of proinflammatory responses by macrophages. Ann Rheum Dis. 2001;60 Suppl 3(Suppl 3):iii6-iii12. https:\/\/doi.org\/10.1136\/ard.60.90003.iii6","DOI":"10.1136\/ard.60.90003.iii6"},{"key":"2600_CR99","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejim.2022.09.010","volume":"106","author":"ZW Wang","year":"2022","unstructured":"Wang ZW, Li M, Li JJ, Liu NF. Association of lipoprotein(a) with all-cause and cause-specific mortality: A prospective cohort study. Eur J Intern Med. 2022;106:63\u201370. https:\/\/doi.org\/10.1016\/j.ejim.2022.09.010.","journal-title":"Eur J Intern Med"},{"key":"2600_CR100","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-pharmtox-031023-100609","volume":"64","author":"E Tasdighi","year":"2024","unstructured":"Tasdighi E, Adhikari R, Almaadawy O, Leucker TM, Blaha MJ. LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics. Annu Rev Pharmacol Toxicol. 2024;64:135\u201357. https:\/\/doi.org\/10.1146\/annurev-pharmtox-031023-100609.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"2600_CR101","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1001\/jamacardio.2024.1882","volume":"9","author":"BJ Arsenault","year":"2024","unstructured":"Arsenault BJ, Loganath K, Girard A, et al. Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis. JAMA Cardiol. 2024;9(9):835\u201342. https:\/\/doi.org\/10.1001\/jamacardio.2024.1882.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"2600_CR102","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.jcmg.2023.02.013","volume":"16","author":"N Marrero","year":"2023","unstructured":"Marrero N, Razavi AC, Boakye E, et al. Association of Inflammation and Lipoprotein(a) With Aortic Valve Calcification. JACC Cardiovasc Imaging. 2023;16(9):1230\u20132. https:\/\/doi.org\/10.1016\/j.jcmg.2023.02.013.","journal-title":"JACC Cardiovasc Imaging"},{"key":"2600_CR103","doi-asserted-by":"publisher","unstructured":"P\u00e9rez de Isla L, Watts GF, Alonso R, et al. Lipoprotein(a), LDL-cholesterol, and hypertension: predictors of the need for aortic valve replacement in familial hypercholesterolaemia. Eur Heart J. 2021;42(22):2201\u20132211. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1066","DOI":"10.1093\/eurheartj\/ehaa1066"},{"issue":"10","key":"2600_CR104","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1080\/00015385.2022.2129183","volume":"77","author":"Z Wang","year":"2022","unstructured":"Wang Z, Li M, Liu N. The nonlinear correlation between lipoprotein (a) and the prevalence of aortic valve calcification in patients with new-onset acute myocardial infarction. Acta Cardiol. 2022;77(10):950\u20139. https:\/\/doi.org\/10.1080\/00015385.2022.2129183.","journal-title":"Acta Cardiol"},{"key":"2600_CR105","doi-asserted-by":"publisher","unstructured":"Yang C, Xu H, Jia R, Jin Z, Zhang C, Yuan J. Global Burden and Improvement Gap of Non-Rheumatic Calcific Aortic Valve Disease: 1990\u20132019 Findings from Global Burden of Disease Study [2019] J Clin Med. 2022;11: 6733. https:\/\/doi.org\/10.3390\/jcm11226733","DOI":"10.3390\/jcm11226733"},{"key":"2600_CR106","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.21037\/jtd-23-480","volume":"15","author":"Z Liu","year":"2023","unstructured":"Liu Z, Su Z, Li W, et al. Global, regional, and national time trends in disability-adjusted life years, mortality, and variable risk factors of non-rheumatic calcified aortic valve disease, 1990\u20132019: an age-period-cohort analysis of the Global Burden of Disease 2019 study. J Thorac Dis. 2023;15:2079\u201397. https:\/\/doi.org\/10.21037\/jtd-23-480.","journal-title":"J Thorac Dis"},{"issue":"6","key":"2600_CR107","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1177\/2047487312451238","volume":"20","author":"I Ferreira-Gonz\u00e1lez","year":"2013","unstructured":"Ferreira-Gonz\u00e1lez I, Pinar-Sopena J, Ribera A, et al. Prevalence of calcific aortic valve disease in the elderly and associated risk factors: a population-based study in a Mediterranean area. Eur J Prev Cardiol. 2013;20(6):1022\u201330. https:\/\/doi.org\/10.1177\/2047487312451238.","journal-title":"Eur J Prev Cardiol"},{"key":"2600_CR108","doi-asserted-by":"publisher","first-page":"742","DOI":"10.7326\/0003-4819-155-11-201112060-00006","volume":"155","author":"S Mora","year":"2011","unstructured":"Mora S, Buring JE, Ridker PM, Cui Y. Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: A cohort study. Ann Intern Med. 2011;155:742. https:\/\/doi.org\/10.7326\/0003-4819-155-11-201112060-00006.","journal-title":"Ann Intern Med"},{"key":"2600_CR109","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","volume":"16","author":"MB Boffa","year":"2019","unstructured":"Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat Rev Cardiol. 2019;16:305\u201318. https:\/\/doi.org\/10.1038\/s41569-018-0153-2.","journal-title":"Nat Rev Cardiol"},{"key":"2600_CR110","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11739-018-1925-8","volume":"14","author":"E Sticchi","year":"2019","unstructured":"Sticchi E, Giusti B, Cordisco A, et al. Role of lipoprotein (a) and LPA KIV2 repeat polymorphism in bicuspid aortic valve stenosis and calcification: a proof of concept study. Intern Emerg Med. 2019;14:45\u201350. https:\/\/doi.org\/10.1007\/s11739-018-1925-8.","journal-title":"Intern Emerg Med"},{"key":"2600_CR111","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3389\/fphar.2020.00685","volume":"11","author":"B Alushi","year":"2020","unstructured":"Alushi B, Curini L, Christopher MR, et al. Calcific aortic valve disease-natural history and future therapeutic strategies. Front Pharmacol. 2020;11:685. https:\/\/doi.org\/10.3389\/fphar.2020.00685.","journal-title":"Front Pharmacol"},{"key":"2600_CR112","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/cvr\/cvad062","volume":"119","author":"P Pantelidis","year":"2023","unstructured":"Pantelidis P. Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis. Cardiovasc Res. 2023;119:1641\u201355. https:\/\/doi.org\/10.1093\/cvr\/cvad062.","journal-title":"Cardiovasc Res"},{"key":"2600_CR113","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/MCO.0000000000000976","volume":"27","author":"NSR Lan","year":"2024","unstructured":"Lan NSR, Khan Z, Watts GF. Lipoprotein(a) and calcific aortic valve disease: current evidence and future directions. Curr Opin Clin Nutr Metab Care. 2024;27:77\u201386. https:\/\/doi.org\/10.1097\/MCO.0000000000000976.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2600_CR114","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1194\/jlr.R051870","volume":"57","author":"G Thanassoulis","year":"2016","unstructured":"Thanassoulis G. Lipoprotein (a) in calcific aortic valve disease: From genomics to novel drug target for aortic stenosis. J Lipid Res. 2016;57:917\u201324. https:\/\/doi.org\/10.1194\/jlr.R051870.","journal-title":"J Lipid Res"},{"key":"2600_CR115","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1093\/eurheartj\/ehad142","volume":"44","author":"H Yu Chen","year":"2023","unstructured":"Yu Chen H, Dina C, Small AM, et al. Dyslipidemia, inflammation, calcification, and adiposity in aortic stenosis: A genome-wide study. Eur Heart J. 2023;44:1927\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad142.","journal-title":"Eur Heart J"},{"key":"2600_CR116","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1161\/CIRCULATIONAHA.122.061451","volume":"147","author":"AM Small","year":"2023","unstructured":"Small AM, Peloso GM, Linefsky J, et al. Multiancestry genome-wide association study of aortic stenosis identifies multiple novel loci in the million veteran program. Circulation. 2023;147:942\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061451.","journal-title":"Circulation"},{"key":"2600_CR117","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2021.11.029","volume":"349","author":"M Kaltoft","year":"2022","unstructured":"Kaltoft M, Sigvardsen PE, Afzal S, et al. Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: The copenhagen general population study. Atherosclerosis. 2022;349:166\u201374. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.11.029.","journal-title":"Atherosclerosis"},{"key":"2600_CR118","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/eurjpc\/zwae100","volume":"31","author":"MK Moore","year":"2024","unstructured":"Moore MK, Jones GT, McCormick S, Williams MJA, Coffey S. Association between lipoprotein(a), LPA genetic risk score, aortic valve disease, and subsequent major adverse cardiovascular events. Eur J Prev Cardiol. 2024;31:1303\u201311. https:\/\/doi.org\/10.1093\/eurjpc\/zwae100.","journal-title":"Eur J Prev Cardiol"},{"key":"2600_CR119","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1161\/CIRCULATIONAHA.104.486738","volume":"111","author":"RV Freeman","year":"2005","unstructured":"Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: Pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111:3316\u201326. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.486738.","journal-title":"Circulation"},{"key":"2600_CR120","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.atherosclerosis.2018.03.025","volume":"272","author":"B Yu","year":"2018","unstructured":"Yu B, Khan K, Hamid Q, et al. Pathological significance of lipoprotein(a) in aortic valve stenosis. Atherosclerosis. 2018;272:168\u201374. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.03.025.","journal-title":"Atherosclerosis"},{"key":"2600_CR121","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jacc.2013.05.105","volume":"63","author":"A Mahmut","year":"2014","unstructured":"Mahmut A, Boulanger M-C, El Husseini D, et al. Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease. J Am Coll Cardiol. 2014;63:460\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.105.","journal-title":"J Am Coll Cardiol"},{"key":"2600_CR122","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.115.016757","volume":"132","author":"R Bouchareb","year":"2015","unstructured":"Bouchareb R, Mahmut A, Nsaibia MJ, et al. Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. Circulation. 2015;132:677\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.016757.","journal-title":"Circulation"},{"key":"2600_CR123","doi-asserted-by":"publisher","unstructured":"Moncla L-HM, Briend M, Boss\u00e9 Y, Mathieu P. Calcific aortic valve disease: Mechanisms, prevention and treatment. Nat Rev Cardiol. 2023;20: 546\u2013559. https:\/\/doi.org\/10.1038\/s41569-023-00845-7","DOI":"10.1038\/s41569-023-00845-7"},{"key":"2600_CR124","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/cvr\/cvx089","volume":"113","author":"MJ Nsaibia","year":"2017","unstructured":"Nsaibia MJ, Boulanger M-C, Bouchareb R, et al. OxLDL-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA\u2013NF-\u03baB pathway. Cardiovasc Res. 2017;113:1351\u201363. https:\/\/doi.org\/10.1093\/cvr\/cvx089.","journal-title":"Cardiovasc Res"},{"key":"2600_CR125","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.3390\/ijms21124501","volume":"21","author":"E Knuplez","year":"2020","unstructured":"Knuplez E, Marsche G. An updated review of pro- and anti-inflammatory properties of plasma lysophosphatidylcholines in the vascular system. Int J Mol Sci. 2020;21:4501. https:\/\/doi.org\/10.3390\/ijms21124501.","journal-title":"Int J Mol Sci"},{"key":"2600_CR126","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1007\/s00018-012-1194-z","volume":"70","author":"S Xu","year":"2013","unstructured":"Xu S, Ogura S, Chen J, Little PJ, Moss J, Liu P. LOX-1 in atherosclerosis: Biological functions and pharmacological modifiers. Cell Mol Life Sci. 2013;70:2859\u201372. https:\/\/doi.org\/10.1007\/s00018-012-1194-z.","journal-title":"Cell Mol Life Sci"},{"key":"2600_CR127","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3390\/ijms22020913","volume":"22","author":"A Di Vito","year":"2021","unstructured":"Di Vito A, Donato A, Presta I, et al. Extracellular matrix in calcific aortic valve disease: Architecture, dynamic and perspectives. Int J Mol Sci. 2021;22:913. https:\/\/doi.org\/10.3390\/ijms22020913.","journal-title":"Int J Mol Sci"},{"key":"2600_CR128","doi-asserted-by":"publisher","unstructured":"Gonzalez Rodriguez A, Schroeder ME, Grim JC, et al. Tumor necrosis factor\u2010\u03b1 promotes and exacerbates calcification in heart valve myofibroblast populations. FASEB J. 2021;35. https:\/\/doi.org\/10.1096\/fj.202002013RR","DOI":"10.1096\/fj.202002013RR"},{"key":"2600_CR129","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jacc.2015.07.045","volume":"66","author":"BG Nordestgaard","year":"2015","unstructured":"Nordestgaard BG, Langsted A. How does elevated lipoprotein(a) cause aortic valve stenosis? J Am Coll Cardiol. 2015;66:1247\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2015.07.045.","journal-title":"J Am Coll Cardiol"},{"key":"2600_CR130","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.812368","volume":"10","author":"J Hu","year":"2022","unstructured":"Hu J, Lei H, Liu L, Xu D. Lipoprotein(a), a lethal player in calcific aortic valve disease. Front Cell Dev Biol. 2022;10: 812368. https:\/\/doi.org\/10.3389\/fcell.2022.812368.","journal-title":"Front Cell Dev Biol"},{"key":"2600_CR131","doi-asserted-by":"publisher","first-page":"6671","DOI":"10.1021\/bi00241a006","volume":"30","author":"DI Simon","year":"1991","unstructured":"Simon DI, Fless GM, Scanu AM, Loscalzo J. Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein(a) and low-density lipoprotein. Biochemistry. 1991;30:6671\u20137. https:\/\/doi.org\/10.1021\/bi00241a006.","journal-title":"Biochemistry"},{"key":"2600_CR132","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood.V98.10.2980","volume":"98","author":"NM Caplice","year":"2001","unstructured":"Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: A novel link between lipoproteins and thrombosis. Blood. 2001;98:2980\u20137. https:\/\/doi.org\/10.1182\/blood.V98.10.2980.","journal-title":"Blood"},{"key":"2600_CR133","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1300\/J381v07n01_07","volume":"7","author":"JM Coggan","year":"2003","unstructured":"Coggan JM. A review of the centers for disease control and prevention web site. J Consum Health Internet. 2003;7:73\u20137. https:\/\/doi.org\/10.1300\/J381v07n01_07.","journal-title":"J Consum Health Internet"},{"key":"2600_CR134","doi-asserted-by":"publisher","unstructured":"Feigin VL, Brainin M, Norrving B, et al. World stroke organization (WSO): Global stroke fact sheet [2022] Int J Stroke. 2022;17: 18\u201329. https:\/\/doi.org\/10.1177\/17474930211065917","DOI":"10.1177\/17474930211065917"},{"key":"2600_CR135","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1161\/STROKEAHA.106.480657","volume":"38","author":"B Smolders","year":"2007","unstructured":"Smolders B, Lemmens R, Thijs V. Lipoprotein (a) and stroke: A meta-analysis of observational studies. Stroke. 2007;38:1959\u201366. https:\/\/doi.org\/10.1161\/STROKEAHA.106.480657.","journal-title":"Stroke"},{"key":"2600_CR136","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/jcp.53.7.487","volume":"53","author":"HJ Milionis","year":"2000","unstructured":"Milionis HJ. Lipoprotein (a) and stroke. J Clin Pathol. 2000;53:487\u201396. https:\/\/doi.org\/10.1136\/jcp.53.7.487.","journal-title":"J Clin Pathol"},{"key":"2600_CR137","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jns.2006.10.004","volume":"252","author":"M Rigal","year":"2007","unstructured":"Rigal M, Ruidavets JB, Viguier A, et al. Lipoprotein (a) and risk of ischemic stroke in young adults. J Neurol Sci. 2007;252:39\u201344. https:\/\/doi.org\/10.1016\/j.jns.2006.10.004.","journal-title":"J Neurol Sci"},{"key":"2600_CR138","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.08.013","volume":"253","author":"A Beheshtian","year":"2016","unstructured":"Beheshtian A, Shitole SG, Segal AZ, et al. Lipoprotein (a) level, apolipoprotein (a) size, and risk of unexplained ischemic stroke in young and middle-aged adults. Atherosclerosis. 2016;253:47\u201353. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.08.013.","journal-title":"Atherosclerosis"},{"key":"2600_CR139","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/01.STR.25.1.74","volume":"25","author":"M Nagayama","year":"1994","unstructured":"Nagayama M, Shinohara Y, Nagayama T. Lipoprotein(a) and ischemic cerebrovascular disease in young adults. Stroke. 1994;25:74\u20138. https:\/\/doi.org\/10.1161\/01.STR.25.1.74.","journal-title":"Stroke"},{"key":"2600_CR140","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1212\/CON.0000000000000416","volume":"23","author":"A Guzik","year":"2017","unstructured":"Guzik A, Bushnell C. Stroke epidemiology and risk factor management. Contin Lifelong Learn Neurol. 2017;23:15\u201339. https:\/\/doi.org\/10.1212\/CON.0000000000000416.","journal-title":"Contin Lifelong Learn Neurol"},{"key":"2600_CR141","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1212\/WNL.37.3.513","volume":"37","author":"G Jurgens","year":"1987","unstructured":"Jurgens G, Koltringer P. Lipoprotein(a) in ischemic cerebrovascular disease: A new approach to the assessment of risk for stroke. Neurology. 1987;37:513\u2013513. https:\/\/doi.org\/10.1212\/WNL.37.3.513.","journal-title":"Neurology"},{"key":"2600_CR142","doi-asserted-by":"publisher","first-page":"212","DOI":"10.21037\/atm.2020.01.38","volume":"8","author":"H Fu","year":"2020","unstructured":"Fu H, Zhang D, Zhu R, et al. Association between lipoprotein(a) concentration and the risk of stroke in the Chinese han population: A retrospective case-control study. Ann Transl Med. 2020;8:212\u2013212. https:\/\/doi.org\/10.21037\/atm.2020.01.38.","journal-title":"Ann Transl Med"},{"key":"2600_CR143","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000319065","volume":"30","author":"B Boden-Albala","year":"2010","unstructured":"Boden-Albala B, Kargman DE, Lin I-F, Paik MC, Sacco RL, Berglund L. Increased stroke risk and lipoprotein(a) in a multiethnic community: The northern manhattan stroke study. Cerebrovasc Dis. 2010;30:237\u201343. https:\/\/doi.org\/10.1159\/000319065.","journal-title":"Cerebrovasc Dis"},{"key":"2600_CR144","doi-asserted-by":"publisher","first-page":"15660","DOI":"10.1038\/s41598-021-95141-0","volume":"11","author":"P Kumar","year":"2021","unstructured":"Kumar P, Swarnkar P, Misra S, Nath M. Lipoprotein (a) level as a risk factor for stroke and its subtype: A systematic review and meta-analysis. Sci Rep. 2021;11:15660. https:\/\/doi.org\/10.1038\/s41598-021-95141-0.","journal-title":"Sci Rep"},{"key":"2600_CR145","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","volume":"242","author":"AH Nave","year":"2015","unstructured":"Nave AH, Lange KS, Leonards CO, et al. Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysis. Atherosclerosis. 2015;242:496\u2013503. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.08.021.","journal-title":"Atherosclerosis"},{"key":"2600_CR146","doi-asserted-by":"publisher","first-page":"1004264","DOI":"10.3389\/fneur.2022.1004264","volume":"13","author":"L Wang","year":"2022","unstructured":"Wang L, Liu L, Zhao Y, Chu M, Teng J. Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study. Front Neurol. 2022;13:1004264. https:\/\/doi.org\/10.3389\/fneur.2022.1004264.","journal-title":"Front Neurol"},{"key":"2600_CR147","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/svn-2018-000226","volume":"4","author":"H Zhang","year":"2019","unstructured":"Zhang H, Li Z, Dai Y, Guo E, Zhang C, Wang Y. Ischaemic stroke etiological classification system: The agreement analysis of CISS. SPARKLE and TOAST Stroke Vasc Neurol. 2019;4:123\u20138. https:\/\/doi.org\/10.1136\/svn-2018-000226.","journal-title":"SPARKLE and TOAST Stroke Vasc Neurol"},{"key":"2600_CR148","doi-asserted-by":"publisher","unstructured":"Arora P, Kalra R, Callas PW, et al. Lipoprotein(a) and risk of ischemic stroke in the REGARDS study. Arterioscler Thromb Vasc Biol. 2019;39: 810-[818. https:\/\/doi.org\/10.1161\/ATVBAHA.118.311857","DOI":"10.1161\/ATVBAHA.118.311857"},{"key":"2600_CR149","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/eurheartj\/11.suppl_E.184","volume":"11","author":"GM Kostner","year":"1990","unstructured":"Kostner GM, Bihari-Varga M. Is the atherogenicity of lp(a) caused by its reactivity with proteoglycans? Eur Heart J. 1990;11:184\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/11.suppl_E.184.","journal-title":"Eur Heart J"},{"key":"2600_CR150","doi-asserted-by":"publisher","unstructured":"Loscalzo J. Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arterioscler Off J Am Heart Assoc Inc. 1990;10: 672\u2013679. https:\/\/doi.org\/10.1161\/01.ATV.10.5.672","DOI":"10.1161\/01.ATV.10.5.672"},{"key":"2600_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2023.120738","volume":"452","author":"Z Youyou","year":"2023","unstructured":"Youyou Z, Ruirui J, Hui W, Zhaoyang L. Association between lipoprotein(a) and ischemic stroke: Fibrinogen as a mediator. J Neurol Sci. 2023;452: 120738. https:\/\/doi.org\/10.1016\/j.jns.2023.120738.","journal-title":"J Neurol Sci"},{"key":"2600_CR152","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0021-9150(98)00232-9","volume":"142","author":"J Peynet","year":"1999","unstructured":"Peynet J, Beaudeux JL, Woimant F, et al. Apolipoprotein(a) size polymorphism in young adults with ischemic stroke. Atherosclerosis. 1999;142:233\u20139. https:\/\/doi.org\/10.1016\/S0021-9150(98)00232-9.","journal-title":"Atherosclerosis"},{"key":"2600_CR153","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/WNR.0000000000000094","volume":"25","author":"W Zhang","year":"2014","unstructured":"Zhang W, Zhang X-A. Prognostic value of serum lipoprotein(a) levels in patients with acute ischemic stroke. NeuroReport. 2014;25:262\u20136. https:\/\/doi.org\/10.1097\/WNR.0000000000000094.","journal-title":"NeuroReport"},{"key":"2600_CR154","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3109\/00207454.2013.772609","volume":"123","author":"E Unal","year":"2013","unstructured":"Unal E, Mungan S, Bilen S, et al. The effects of lipoprotein(a) and homocysteine on prognosis and risk factors in acute ischemic stroke. Int J Neurosci. 2013;123:532\u20136. https:\/\/doi.org\/10.3109\/00207454.2013.772609.","journal-title":"Int J Neurosci"},{"issue":"3","key":"2600_CR155","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","volume":"83","author":"E Bj\u00f6rnson","year":"2024","unstructured":"Bj\u00f6rnson E, Adiels M, Taskinen MR, et al. Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis. J Am Coll Cardiol. 2024;83(3):385\u201395. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.039.","journal-title":"J Am Coll Cardiol"},{"issue":"9474","key":"2600_CR156","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/S0140-6736(05)66621-4","volume":"365","author":"JJ McMurray","year":"2005","unstructured":"McMurray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365(9474):1877\u201389. https:\/\/doi.org\/10.1016\/S0140-6736(05)66621-4.","journal-title":"Lancet"},{"key":"2600_CR157","doi-asserted-by":"publisher","first-page":"1260050","DOI":"10.3389\/fendo.2023.1260050","volume":"14","author":"X Yan","year":"2023","unstructured":"Yan X, Gong J, Wang Z, Wang F, Qi C. Association of lipoprotein(a) with left ventricular hypertrophy assessed by electrocardiogram in adults: a large cross-sectional study. Front Endocrinol (Lausanne). 2023;14:1260050. https:\/\/doi.org\/10.3389\/fendo.2023.1260050.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2600_CR158","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s10741-023-10333-2","volume":"28","author":"W Masson","year":"2023","unstructured":"Masson W, Barbagelata L, Lavalle-Cobo A, Corral P, Nogueira JP. Lipoprotein(a) and heart failure: a systematic review. Heart Fail Rev. 2023;28(6):1307\u201314. https:\/\/doi.org\/10.1007\/s10741-023-10333-2.","journal-title":"Heart Fail Rev"},{"issue":"4","key":"2600_CR159","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102439","volume":"49","author":"S Singh","year":"2024","unstructured":"Singh S, Baars DP, Aggarwal K, Desai R, Singh D, Pinto-Sietsma SJ. Association between lipoprotein (a) and risk of heart failure: A systematic review and meta-analysis of Mendelian randomization studies. Curr Probl Cardiol. 2024;49(4): 102439. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102439.","journal-title":"Curr Probl Cardiol"},{"issue":"4","key":"2600_CR160","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1002\/ehf2.13933","volume":"9","author":"Z Li","year":"2022","unstructured":"Li Z, Liu J, Shen J, et al. Association of lipoprotein (a) and 1 year prognosis in patients with heart failure with reduced ejection fraction. ESC Heart Fail. 2022;9(4):2399\u2013406. https:\/\/doi.org\/10.1002\/ehf2.13933.","journal-title":"ESC Heart Fail"},{"key":"2600_CR161","doi-asserted-by":"publisher","first-page":"1466146","DOI":"10.3389\/fcvm.2024.1466146","volume":"11","author":"B Zhang","year":"2024","unstructured":"Zhang B, Xu Y, Huang X, et al. Lipoprotein(a) as a novel biomarker for predicting adverse outcomes in ischemic heart failure. Front Cardiovasc Med. 2024;11:1466146. https:\/\/doi.org\/10.3389\/fcvm.2024.1466146.","journal-title":"Front Cardiovasc Med"},{"key":"2600_CR162","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.atherosclerosis.2017.05.014","volume":"262","author":"A Agarwala","year":"2017","unstructured":"Agarwala A, Pokharel Y, Saeed A, et al. The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study. Atherosclerosis. 2017;262:131\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.05.014.","journal-title":"Atherosclerosis"},{"issue":"1","key":"2600_CR163","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24083","volume":"36","author":"B Wu","year":"2022","unstructured":"Wu B, Zhang Z, Long J, Zhao H, Zeng F. Association between lipoprotein (a) and heart failure with reduced ejection fraction development. J Clin Lab Anal. 2022;36(1): e24083. https:\/\/doi.org\/10.1002\/jcla.24083.","journal-title":"J Clin Lab Anal"},{"issue":"11","key":"2600_CR164","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1373\/clinchem.2016.270751","volume":"63","author":"J Cao","year":"2017","unstructured":"Cao J, Steffen BT, Guan W, et al. Evaluation of Lipoprotein(a) Electrophoretic and Immunoassay Methods in Discriminating Risk of Calcific Aortic Valve Disease and Incident Coronary Heart Disease: The Multi-Ethnic Study of Atherosclerosis. Clin Chem. 2017;63(11):1705\u201313. https:\/\/doi.org\/10.1373\/clinchem.2016.270751.","journal-title":"Clin Chem"},{"key":"2600_CR165","doi-asserted-by":"publisher","unstructured":"Zhang J, Jia L, Yang Y, Xiao A, Lin X. Lipoprotein (a) and myocardial infarction: impact on long-term mortality. Lipids Health Dis. 2023;22(1):70. Published 2023 Jun 9. https:\/\/doi.org\/10.1186\/s12944-023-01841-z","DOI":"10.1186\/s12944-023-01841-z"},{"issue":"17","key":"2600_CR166","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021660","volume":"11","author":"JE John","year":"2022","unstructured":"John JE, Claggett B, Skali H, et al. Coronary Artery Disease and Heart Failure With Preserved Ejection Fraction: The ARIC Study. J Am Heart Assoc. 2022;11(17): e021660. https:\/\/doi.org\/10.1161\/JAHA.121.021660.","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"2600_CR167","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.jacc.2022.02.018","volume":"79","author":"P Mohammadi-Shemirani","year":"2022","unstructured":"Mohammadi-Shemirani P, Chong M, Narula S, et al. Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study. J Am Coll Cardiol. 2022;79(16):1579\u201390. https:\/\/doi.org\/10.1016\/j.jacc.2022.02.018.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2600_CR168","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/clc.24086","volume":"46","author":"M Yang","year":"2023","unstructured":"Yang M, Nasr B, Liu J, Du Y, Yang J. The association between lipoprotein(a) and atrial fibrillation: A systemic review and meta-analysis. Clin Cardiol. 2023;46(8):899\u2013905. https:\/\/doi.org\/10.1002\/clc.24086.","journal-title":"Clin Cardiol"},{"key":"2600_CR169","doi-asserted-by":"publisher","unstructured":"Singh S, Baars DP, Desai R, Singh D, Pinto-Sietsma SJ. Association Between Lipoprotein (a) and Risk of Atrial Fibrillation: A Systematic Review and Meta-analysis of Mendelian Randomization Studies. Curr Probl Cardiol. 2024;49(1 Pt A):102024. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102024","DOI":"10.1016\/j.cpcardiol.2023.102024"},{"issue":"1","key":"2600_CR170","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12944-022-01682-2","volume":"21","author":"J Song","year":"2022","unstructured":"Song J, Zhang X, Wei M, Bo Y, Zhou X, Tang B. Association between lipoprotein(a) and thromboembolism in patients with non-valvular atrial fibrillation: a cross-sectional study. Lipids Health Dis. 2022;21(1):78. https:\/\/doi.org\/10.1186\/s12944-022-01682-2.","journal-title":"Lipids Health Dis"},{"issue":"24","key":"2600_CR171","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.jacc.2023.10.009","volume":"82","author":"PE Thomas","year":"2023","unstructured":"Thomas PE, Vedel-Krogh S, Nielsen SF, Nordestgaard BG, Kamstrup PR. Lipoprotein(a) and Risks of Peripheral Artery Disease, Abdominal Aortic Aneurysm, and Major Adverse Limb Events. J Am Coll Cardiol. 2023;82(24):2265\u201376. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.009.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2600_CR172","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/clc.24003","volume":"46","author":"C Yi","year":"2023","unstructured":"Yi C, Junyi G, Fengju L, Qing Z, Jie C. Association between lipoprotein(a) and peripheral arterial disease in coronary artery bypass grafting patients. Clin Cardiol. 2023;46(5):512\u201320. https:\/\/doi.org\/10.1002\/clc.24003.","journal-title":"Clin Cardiol"},{"issue":"4","key":"2600_CR173","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/1358863X221091320","volume":"27","author":"W Masson","year":"2022","unstructured":"Masson W, Lobo M, Barbagelata L, Molinero G, Bluro I, Nogueira JP. Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic review. Vasc Med. 2022;27(4):385\u201391. https:\/\/doi.org\/10.1177\/1358863X221091320.","journal-title":"Vasc Med"},{"key":"2600_CR174","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.atherosclerosis.2022.10.002","volume":"363","author":"B Zierfuss","year":"2022","unstructured":"Zierfuss B, H\u00f6baus C, Feldscher A, et al. Lipoprotein (a) and long-term outcome in patients with peripheral artery disease undergoing revascularization. Atherosclerosis. 2022;363:94\u2013101. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.10.002.","journal-title":"Atherosclerosis"},{"key":"2600_CR175","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/HYPERTENSIONAHA.122.20189","volume":"80","author":"R Rikhi","year":"2023","unstructured":"Rikhi R, Bhatia HS, Schaich CL, et al. Association of Lp(a) (Lipoprotein[a]) and Hypertension in Primary Prevention of Cardiovascular Disease: The MESA. Hypertension. 2023;80:352\u201360. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.20189.","journal-title":"Hypertension"},{"key":"2600_CR176","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.120.003354","volume":"14","author":"BA Satterfield","year":"2021","unstructured":"Satterfield BA, Dikilitas O, Safarova MS, et al. Associations of genetically predicted lp(a) (lipoprotein [a]) levels with cardiovascular traits in individuals of european and african ancestry. Circ Genomic Precis Med. 2021;14: e003354. https:\/\/doi.org\/10.1161\/CIRCGEN.120.003354.","journal-title":"Circ Genomic Precis Med"},{"issue":"1","key":"2600_CR177","doi-asserted-by":"publisher","first-page":"14433","DOI":"10.1038\/s41598-024-65231-w","volume":"14","author":"N Vazquez-Agra","year":"2024","unstructured":"Vazquez-Agra N, Cruces-Sande A, Barbosa-Gouveia S, et al. Assessing the relationship between lipoprotein(a) levels and blood pressure among hypertensive patients beyond conventional measures. An observational study Sci Rep. 2024;14(1):14433. https:\/\/doi.org\/10.1038\/s41598-024-65231-w.","journal-title":"An observational study Sci Rep"},{"key":"2600_CR178","doi-asserted-by":"publisher","first-page":"13363","DOI":"10.3390\/ijms241713363","volume":"24","author":"G Brosolo","year":"2023","unstructured":"Brosolo G, Da Porto A, Marcante S, et al. Lipoprotein(a): Just an innocent bystander in arterial hypertension? Int J Mol Sci. 2023;24:13363. https:\/\/doi.org\/10.3390\/ijms241713363.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"2600_CR179","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1001\/jama.1997.03540450045033","volume":"277","author":"LA Sechi","year":"1997","unstructured":"Sechi LA, Kronenberg F, De Carli S, et al. Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension. JAMA. 1997;277(21):1689\u201395.","journal-title":"JAMA"},{"key":"2600_CR180","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11906-021-01161-6","volume":"23","author":"NC Ward","year":"2021","unstructured":"Ward NC, Nolde JM, Chan J, Carnagarin R, Watts GF, Schlaich MP. Lipoprotein (a) and Hypertension. Curr Hypertens Rep. 2021;23:44. https:\/\/doi.org\/10.1007\/s11906-021-01161-6.","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"2600_CR181","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1681\/ASN.V111105","volume":"11","author":"F Kronenberg","year":"2000","unstructured":"Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol. 2000;11(1):105\u201315. https:\/\/doi.org\/10.1681\/ASN.V111105.","journal-title":"J Am Soc Nephrol"},{"key":"2600_CR182","doi-asserted-by":"publisher","unstructured":"Shiyovich A, Berman AN, Besser SA, et al. Lipoprotein(a) as a cardiovascular risk factor among patients with and without diabetes Mellitus: the Mass General Brigham Lp(a) Registry. Cardiovasc Diabetol. 2024;23(1):257. Published 2024 Jul 18. https:\/\/doi.org\/10.1186\/s12933-024-02348-2","DOI":"10.1186\/s12933-024-02348-2"},{"issue":"10","key":"2600_CR183","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.numecd.2020.05.011","volume":"30","author":"F Moosaie","year":"2020","unstructured":"Moosaie F, Firouzabadi FD, Abouhamzeh K, et al. Lp(a) and Apo-lipoproteins as predictors for micro- and macrovascular complications of diabetes: A case-cohort study. Nutr Metab Cardiovasc Dis. 2020;30(10):1723\u201331. https:\/\/doi.org\/10.1016\/j.numecd.2020.05.011.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2600_CR184","doi-asserted-by":"publisher","unstructured":"Sheng L, Yang Y, Zhou Y. Association between lipoprotein(a) and diabetic peripheral neuropathy in patients with type 2 diabetes: a meta-analysis. Diabetol Metab Syndr. 2025;17(1):76. Published 2025 Mar 4. https:\/\/doi.org\/10.1186\/s13098-025-01621-y","DOI":"10.1186\/s13098-025-01621-y"},{"issue":"5","key":"2600_CR185","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1194\/jlr.C085639","volume":"59","author":"S Tsimikas","year":"2018","unstructured":"Tsimikas S. In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes. J Lipid Res. 2018;59(5):741\u20134. https:\/\/doi.org\/10.1194\/jlr.C085639.","journal-title":"J Lipid Res"},{"key":"2600_CR186","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2018.12.022","volume":"282","author":"A Saeed","year":"2019","unstructured":"Saeed A, Sun W, Agarwala A, et al. Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study. Atherosclerosis. 2019;282:52\u20136. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.12.022.","journal-title":"Atherosclerosis"},{"key":"2600_CR187","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.atherosclerosis.2022.04.016","volume":"349","author":"C Lamina","year":"2022","unstructured":"Lamina C, Ward NC. Lipoprotein (a) and diabetes mellitus. Atherosclerosis. 2022;349:63\u201371. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.016.","journal-title":"Atherosclerosis"},{"key":"2600_CR188","doi-asserted-by":"publisher","unstructured":"Kostner KM, Kostner GM. Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus. Int J Mol Sci. 2022;23(7):3584. Published 2022 Mar 25. https:\/\/doi.org\/10.3390\/ijms23073584","DOI":"10.3390\/ijms23073584"},{"issue":"2","key":"2600_CR189","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/MED.0000000000000597","volume":"28","author":"NC Ward","year":"2021","unstructured":"Ward NC, Vickneswaran S, Watts GF. Lipoprotein (a) and diabetes mellitus: causes and consequences. Curr Opin Endocrinol Diabetes Obes. 2021;28(2):181\u20137. https:\/\/doi.org\/10.1097\/MED.0000000000000597.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"7","key":"2600_CR190","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.2337\/dc19-0274","volume":"42","author":"JL Jin","year":"2019","unstructured":"Jin JL, Cao YX, Zhang HW, et al. Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Prediabetes or Diabetes. Diabetes Care. 2019;42(7):1312\u20138. https:\/\/doi.org\/10.2337\/dc19-0274.","journal-title":"Diabetes Care"},{"key":"2600_CR191","doi-asserted-by":"publisher","unstructured":"Rikhi R, Haidar A, Bhatia HS, et al. Association of lipoprotein(a) and diabetes in primary prevention of coronary heart disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. Published online March 27, 2025. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119179","DOI":"10.1016\/j.atherosclerosis.2025.119179"},{"key":"2600_CR192","doi-asserted-by":"publisher","unstructured":"Kotani K, Yamada S, Takahashi H, Iwazu Y, Yamada T. The Ratio of Oxidized Lipoprotein(a) to Native Lipoprotein(a) and the Endothelial Function in Patients with Type 2 Diabetes Mellitus. Int J Mol Sci. 2019;20(19):4909. Published 2019 Oct 3. https:\/\/doi.org\/10.3390\/ijms20194909","DOI":"10.3390\/ijms20194909"},{"key":"2600_CR193","doi-asserted-by":"publisher","unstructured":"Ren X, Zhang Z, Yan Z. Association Between Lipoprotein (A) and Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis. Front Endocrinol (Lausanne). 2021;12:633529. Published 2021 Mar 24. https:\/\/doi.org\/10.3389\/fendo.2021.633529","DOI":"10.3389\/fendo.2021.633529"},{"issue":"7","key":"2600_CR194","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.2337\/dc06-0546","volume":"29","author":"B Kollerits","year":"2006","unstructured":"Kollerits B, Auinger M, Reisig V, et al. Lipoprotein(a) as a predictor of cardiovascular disease in a prospectively followed cohort of patients with type 1 diabetes. Diabetes Care. 2006;29(7):1661\u20133. https:\/\/doi.org\/10.2337\/dc06-0546.","journal-title":"Diabetes Care"},{"issue":"2","key":"2600_CR195","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s005920300007","volume":"40","author":"ML Koschinsky","year":"2003","unstructured":"Koschinsky ML, Marcovina SM. The relationship between lipoprotein(a) and the complications of diabetes mellitus. Acta Diabetol. 2003;40(2):65\u201376. https:\/\/doi.org\/10.1007\/s005920300007.","journal-title":"Acta Diabetol"},{"issue":"11 Suppl","key":"2600_CR196","doi-asserted-by":"publisher","first-page":"I31","DOI":"10.1161\/CIRCULATIONAHA.106.680157","volume":"116","author":"M Boodhwani","year":"2007","unstructured":"Boodhwani M, Sodha NR, Mieno S, et al. Functional, cellular, and molecular characterization of the angiogenic response to chronic myocardial ischemia in diabetes. Circulation. 2007;116(11 Suppl):I31\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.680157.","journal-title":"Circulation"},{"key":"2600_CR197","doi-asserted-by":"publisher","unstructured":"Sheashaa H, Mousa H, Abbas MT, et al. Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature. Biomolecules. 2025;15(2):162. Published 2025 Jan 22. https:\/\/doi.org\/10.3390\/biom15020162","DOI":"10.3390\/biom15020162"},{"key":"2600_CR198","doi-asserted-by":"publisher","unstructured":"Ugov\u0161ek S, \u0160ebe\u0161tjen M. Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation. Biomolecules. 2021;12(1):26. Published 2021 Dec 24. https:\/\/doi.org\/10.3390\/biom12010026","DOI":"10.3390\/biom12010026"},{"issue":"27","key":"2600_CR199","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1093\/eurheartj\/ehy334","volume":"39","author":"R Verbeek","year":"2018","unstructured":"Verbeek R, Hoogeveen RM, Langsted A, et al. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J. 2018;39(27):2589\u201396. https:\/\/doi.org\/10.1093\/eurheartj\/ehy334.","journal-title":"Eur Heart J"},{"key":"2600_CR200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2019.10.044","volume":"501","author":"Y Hu","year":"2020","unstructured":"Hu Y, Tao JY, Cai DP, He YM. Interaction of lipoprotein(a) with low-density lipoprotein cholesterol on first incident acute myocardial infarction. Clin Chim Acta. 2020;501:1\u20135. https:\/\/doi.org\/10.1016\/j.cca.2019.10.044.","journal-title":"Clin Chim Acta"},{"key":"2600_CR201","doi-asserted-by":"publisher","unstructured":"Shen Y, Chen S, Dai Y, et al. Lipoprotein (a) interactions with cholesterol-containing lipids on angiographic coronary collateralization in type 2 diabetic patients with chronic total occlusion. Cardiovasc Diabetol. 2019;18(1):82. Published 2019 Jun 24. https:\/\/doi.org\/10.1186\/s12933-019-0888-z","DOI":"10.1186\/s12933-019-0888-z"},{"issue":"4","key":"2600_CR202","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1161\/CIRCULATIONAHA.124.069556","volume":"151","author":"HS Bhatia","year":"2025","unstructured":"Bhatia HS, Wandel S, Willeit P, et al. Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis. Circulation. 2025;151(4):312\u201321. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069556.","journal-title":"Circulation"},{"issue":"19","key":"2600_CR203","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","volume":"63","author":"R Alonso","year":"2014","unstructured":"Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014;63(19):1982\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.063.","journal-title":"J Am Coll Cardiol"},{"key":"2600_CR204","doi-asserted-by":"publisher","unstructured":"Hurt-Camejo E, Olsson U, Wiklund O, Bondjers G, Camejo G. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol. 1997;17(6):1011\u20131017. https:\/\/doi.org\/10.1161\/01.atv.17.6.1011","DOI":"10.1161\/01.atv.17.6.1011"},{"issue":"3","key":"2600_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2020.158869","volume":"1866","author":"F Bigazzi","year":"2021","unstructured":"Bigazzi F, Minichilli F, Sbrana F, et al. Gender difference in lipoprotein(a) concentration as a predictor of coronary revascularization in patients with known coronary artery disease. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866(3): 158869. https:\/\/doi.org\/10.1016\/j.bbalip.2020.158869.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"9","key":"2600_CR206","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/0003319719854872","volume":"70","author":"M Kouvari","year":"2019","unstructured":"Kouvari M, Panagiotakos DB, Chrysohoou C, et al. Lipoprotein (a) and 10-year Cardiovascular Disease Incidence in Apparently Healthy Individuals: A Sex-based Sensitivity Analysis from ATTICA Cohort Study. Angiology. 2019;70(9):819\u201329. https:\/\/doi.org\/10.1177\/0003319719854872.","journal-title":"Angiology"},{"issue":"4","key":"2600_CR207","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.120.003271","volume":"14","author":"J Guertin","year":"2021","unstructured":"Guertin J, Kaiser Y, Manikpurage H, et al. Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic LPA Gene Expression Levels With Cardiovascular Outcomes: Mendelian Randomization and Observational Analyses. Circ Genom Precis Med. 2021;14(4): e003271. https:\/\/doi.org\/10.1161\/CIRCGEN.120.003271.","journal-title":"Circ Genom Precis Med"},{"issue":"2","key":"2600_CR208","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1517\/13543784.2011.548804","volume":"20","author":"G Gaeta","year":"2011","unstructured":"Gaeta G, Lanero S, Barra S, et al. Sex hormones and lipoprotein(a) concentration. Expert Opin Investig Drugs. 2011;20(2):221\u201338. https:\/\/doi.org\/10.1517\/13543784.2011.548804.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"2600_CR209","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/01.cir.87.4.1135","volume":"87","author":"JL Jenner","year":"1993","unstructured":"Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study Circulation. 1993;87(4):1135\u201341. https:\/\/doi.org\/10.1161\/01.cir.87.4.1135.","journal-title":"The Framingham Offspring Study Circulation"},{"key":"2600_CR210","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.05.019","volume":"384","author":"JM Assini","year":"2023","unstructured":"Assini JM, Clark JR, Youssef A, et al. High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner. Atherosclerosis. 2023;384: 117150. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.05.019.","journal-title":"Atherosclerosis"},{"key":"2600_CR211","doi-asserted-by":"publisher","unstructured":"Schreiner PJ, Heiss G, Tyroler HA, Morrisett JD, Davis CE, Smith R. Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 1996;16(3):471\u2013478. https:\/\/doi.org\/10.1161\/01.atv.16.3.471","DOI":"10.1161\/01.atv.16.3.471"},{"issue":"4","key":"2600_CR212","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1016\/j.jacl.2024.04.122","volume":"18","author":"VA Bittner","year":"2024","unstructured":"Bittner VA, Schwartz GG, Bhatt DL, et al. Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study. J Clin Lipidol. 2024;18(4):e548\u201361. https:\/\/doi.org\/10.1016\/j.jacl.2024.04.122.","journal-title":"J Clin Lipidol"},{"key":"2600_CR213","doi-asserted-by":"publisher","unstructured":"Johannsson G, Oscarsson J, Ros\u00e9n T, et al. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes. Arterioscler Thromb Vasc Biol. 1995;15(12):2142\u20132150. https:\/\/doi.org\/10.1161\/01.atv.15.12.2142","DOI":"10.1161\/01.atv.15.12.2142"},{"key":"2600_CR214","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.cca.2018.06.004","volume":"484","author":"FM Cui","year":"2018","unstructured":"Cui FM, Fang F, He YM, Cai DP, He J, Yang XJ. Establishing age and sex dependent upper reference limits for the plasma lipoprotein (a) in a Chinese health check-up population and according to its relative risk of primary myocardial infarction. Clin Chim Acta. 2018;484:232\u20136. https:\/\/doi.org\/10.1016\/j.cca.2018.06.004.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"2600_CR215","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41390-024-03108-4","volume":"96","author":"PE St\u00fcrzebecher","year":"2024","unstructured":"St\u00fcrzebecher PE, Uttinger KL, Vogel M, et al. Lipoprotein(a) serum concentrations in children in relation to body mass index, age and sex. Pediatr Res. 2024;96(1):177\u201383. https:\/\/doi.org\/10.1038\/s41390-024-03108-4.","journal-title":"Pediatr Res"},{"issue":"4","key":"2600_CR216","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1194\/jlr.D800050-JLR200","volume":"50","author":"MB Lanktree","year":"2009","unstructured":"Lanktree MB, Rajakumar C, Brunt JH, Koschinsky ML, Connelly PW, Hegele RA. Determination of lipoprotein(a) kringle repeat number from genomic DNA: copy number variation genotyping using qPCR. J Lipid Res. 2009;50(4):768\u201372. https:\/\/doi.org\/10.1194\/jlr.D800050-JLR200.","journal-title":"J Lipid Res"},{"key":"2600_CR217","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","volume":"349","author":"S Coassin","year":"2022","unstructured":"Coassin S, Kronenberg F. Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene. Atherosclerosis. 2022;349:17\u201335. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.003.","journal-title":"Atherosclerosis"},{"issue":"4","key":"2600_CR218","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/hmg\/2.4.361","volume":"2","author":"YY van der Hoek","year":"1993","unstructured":"van der Hoek YY, Wittekoek ME, Beisiegel U, Kastelein JJ, Koschinsky ML. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum Mol Genet. 1993;2(4):361\u20136. https:\/\/doi.org\/10.1093\/hmg\/2.4.361.","journal-title":"Hum Mol Genet"},{"key":"2600_CR219","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","volume":"289","author":"H Scharnagl","year":"2019","unstructured":"Scharnagl H, Stojakovic T, Dieplinger B, et al. Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. Atherosclerosis. 2019;289:206\u201313. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.08.015.","journal-title":"Atherosclerosis"},{"issue":"1","key":"2600_CR220","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/0004563220968473","volume":"58","author":"J Cegla","year":"2021","unstructured":"Cegla J, France M, Marcovina SM, Neely RDG. Lp(a): When and how to measure it. Ann Clin Biochem. 2021;58(1):16\u201321. https:\/\/doi.org\/10.1177\/0004563220968473.","journal-title":"Ann Clin Biochem"},{"issue":"9","key":"2600_CR221","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1093\/clinchem\/38.9.1873","volume":"38","author":"DS Sgoutas","year":"1992","unstructured":"Sgoutas DS, Tuten T. Effect of freezing and thawing of serum on the immunoassay of lipoprotein(a). Clin Chem. 1992;38(9):1873\u20137.","journal-title":"Clin Chem"},{"key":"2600_CR222","doi-asserted-by":"publisher","unstructured":"Dati F, Tate JR, Marcovina SM, Steinmetz A; International Federation of Clinical Chemistry and Laboratory Medicine; IFCC Working Group for Lipoprotein(a) Assay Standardization. First WHO\/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay--Lp(a) SRM 2B. Clin Chem Lab Med. 2004;42(6):670\u2013676. https:\/\/doi.org\/10.1515\/CCLM.2004.114","DOI":"10.1515\/CCLM.2004.114"},{"issue":"3","key":"2600_CR223","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","volume":"18","author":"ML Koschinsky","year":"2024","unstructured":"Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024;18(3):e308\u201319. https:\/\/doi.org\/10.1016\/j.jacl.2024.03.001.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"2600_CR224","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-2275(20)38555-2","volume":"29","author":"A Gries","year":"1988","unstructured":"Gries A, Fievet C, Marcovina S, et al. Interaction of LDL, Lp[a], and reduced Lp[a] with monoclonal antibodies against apoB. J Lipid Res. 1988;29(1):1\u20138.","journal-title":"J Lipid Res"},{"issue":"2","key":"2600_CR225","first-page":"105","volume":"25","author":"J Tate","year":"2004","unstructured":"Tate J, Ward G. Interferences in immunoassay. Clin Biochem Rev. 2004;25(2):105\u201320.","journal-title":"Clin Biochem Rev"},{"issue":"5","key":"2600_CR226","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0022-2275(20)38320-6","volume":"30","author":"GM Fless","year":"1989","unstructured":"Fless GM, Snyder ML, Scanu AM. Enzyme-linked immunoassay for Lp[a]. J Lipid Res. 1989;30(5):651\u201362.","journal-title":"J Lipid Res"},{"issue":"6","key":"2600_CR227","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/clinchem\/38.6.853","volume":"38","author":"G J\u00fcrgens","year":"1992","unstructured":"J\u00fcrgens G, Hermann A, Aktuna D, Petek W. Dissociation-enhanced lanthanide fluorescence immunoassay of lipoprotein(a) in serum. Clin Chem. 1992;38(6):853\u20139.","journal-title":"Clin Chem"},{"key":"2600_CR228","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0009-3084(94)90144-9","volume":"67\u201368","author":"BA Kottke","year":"1994","unstructured":"Kottke BA, Bren ND. A particle concentration fluorescence immunoassay for Lp(a). Chem Phys Lipids. 1994;67\u201368:249\u201356. https:\/\/doi.org\/10.1016\/0009-3084(94)90144-9.","journal-title":"Chem Phys Lipids"},{"issue":"1","key":"2600_CR229","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0009-8981(95)06001-3","volume":"235","author":"EA Molinari","year":"1995","unstructured":"Molinari EA, Pichler PF, Grillhofer H, Kostner GM. Immunoturbidimetric determination of lipoprotein(a): improvement in the measurement of turbid and triglyceride-rich samples. Clin Chim Acta. 1995;235(1):59\u201369. https:\/\/doi.org\/10.1016\/0009-8981(95)06001-3.","journal-title":"Clin Chim Acta"},{"key":"2600_CR230","doi-asserted-by":"publisher","unstructured":"Liu Y, Li M, Zhang H, et al. Development of a fully automated latex-enhanced immunoturbidimetric method for quantitative serum Lp(a) measurement. Biotechnol Lett. 2025;47(2):31. Published 2025 Mar 6. https:\/\/doi.org\/10.1007\/s10529-025-03564-w","DOI":"10.1007\/s10529-025-03564-w"},{"issue":"6","key":"2600_CR231","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/MOL.0000000000000855","volume":"33","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG. Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees. Curr Opin Lipidol. 2022;33(6):342\u201352. https:\/\/doi.org\/10.1097\/MOL.0000000000000855.","journal-title":"Curr Opin Lipidol"},{"key":"2600_CR232","doi-asserted-by":"publisher","unstructured":"Pino BD, Gorini F, Gaggini M, Landi P, Pingitore A, Vassalle C. Lipoprotein(a), Cardiovascular Events and Sex Differences: A Single Cardiological Unit Experience. J Clin Med. 2023;12(3):764. Published 2023 Jan 18. https:\/\/doi.org\/10.3390\/jcm12030764","DOI":"10.3390\/jcm12030764"},{"key":"2600_CR233","doi-asserted-by":"publisher","unstructured":"Nissen SE, Wolski K, Cho L, et al. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease [published correction appears in Open Heart. 2022 Nov;9(2):e002060corr1. https:\/\/doi.org\/10.1136\/openhrt-2022-002060corr1.]. Open Heart. 2022;9(2):e002060. https:\/\/doi.org\/10.1136\/openhrt-2022-002060","DOI":"10.1136\/openhrt-2022-002060corr1"},{"issue":"5","key":"2600_CR234","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4239\/wjd.v3.i5.105","volume":"3","author":"R Chandni","year":"2012","unstructured":"Chandni R, Ramamoorthy KP. Lipoprotein(a) in type 2 diabetic subjects and its relationship to diabetic microvascular complications. World J Diabetes. 2012;3(5):105\u20139. https:\/\/doi.org\/10.4239\/wjd.v3.i5.105.","journal-title":"World J Diabetes"},{"issue":"4","key":"2600_CR235","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1194\/jlr.R083626","volume":"59","author":"JC Hopewell","year":"2018","unstructured":"Hopewell JC, Haynes R, Baigent C. The role of lipoprotein (a) in chronic kidney disease. J Lipid Res. 2018;59(4):577\u201385. https:\/\/doi.org\/10.1194\/jlr.R083626.","journal-title":"J Lipid Res"},{"issue":"1","key":"2600_CR236","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","volume":"40","author":"CM Madsen","year":"2020","unstructured":"Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-Lowering by 50 mg\/dL (105 nmol\/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. Arterioscler Thromb Vasc Biol. 2020;40(1):255\u201366. https:\/\/doi.org\/10.1161\/ATVBAHA.119.312951.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"2600_CR237","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","volume":"30","author":"HN Ginsberg","year":"2016","unstructured":"Ginsberg HN, Rader DJ, Raal FJ, et al. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg\/dl or Higher. Cardiovasc Drugs Ther. 2016;30(5):473\u201383. https:\/\/doi.org\/10.1007\/s10557-016-6685-y.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"2600_CR238","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","volume":"169","author":"DJ Kereiakes","year":"2015","unstructured":"Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906-915.e13. https:\/\/doi.org\/10.1016\/j.ahj.2015.03.004.","journal-title":"Am Heart J"},{"issue":"5","key":"2600_CR239","doi-asserted-by":"publisher","first-page":"164","DOI":"10.18773\/austprescr.2016.060","volume":"39","author":"MM Page","year":"2016","unstructured":"Page MM, Watts GF. PCSK9 inhibitors - mechanisms of action. Aust Prescr. 2016;39(5):164\u20137. https:\/\/doi.org\/10.18773\/austprescr.2016.060.","journal-title":"Aust Prescr"},{"issue":"33","key":"2600_CR240","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1093\/eurheartj\/ehy862","volume":"40","author":"LCA Stiekema","year":"2019","unstructured":"Stiekema LCA, Stroes ESG, Verweij SL, et al. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment. Eur Heart J. 2019;40(33):2775\u201381. https:\/\/doi.org\/10.1093\/eurheartj\/ehy862.","journal-title":"Eur Heart J"},{"key":"2600_CR241","doi-asserted-by":"publisher","unstructured":"Rehman WU, Yarkoni M, Ilyas MA, et al. Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. J Cardiovasc Dev Dis. 2024;11(5):152. Published 2024 May 16. https:\/\/doi.org\/10.3390\/jcdd11050152","DOI":"10.3390\/jcdd11050152"},{"issue":"8","key":"2600_CR242","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28(8):1672\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01936-7.","journal-title":"Nat Med"},{"issue":"2","key":"2600_CR243","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11883-023-01184-1","volume":"26","author":"JJP Kastelein","year":"2024","unstructured":"Kastelein JJP, Hsieh A, Dicklin MR, Ditmarsch M, Davidson MH. Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Curr Atheroscler Rep. 2024;26(2):35\u201344. https:\/\/doi.org\/10.1007\/s11883-023-01184-1.","journal-title":"Curr Atheroscler Rep"},{"issue":"14","key":"2600_CR244","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","volume":"118","author":"NS Nurmohamed","year":"2022","unstructured":"Nurmohamed NS, Ditmarsch M, Kastelein JJP. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Cardiovasc Res. 2022;118(14):2919\u201331. https:\/\/doi.org\/10.1093\/cvr\/cvab350.","journal-title":"Cardiovasc Res"},{"issue":"8A","key":"2600_CR245","doi-asserted-by":"publisher","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","volume":"101","author":"VS Kamanna","year":"2008","unstructured":"Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101(8A):20B-26B. https:\/\/doi.org\/10.1016\/j.amjcard.2008.02.029.","journal-title":"Am J Cardiol"},{"issue":"11","key":"2600_CR246","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1194\/jlr.M029769","volume":"53","author":"I Chennamsetty","year":"2012","unstructured":"Chennamsetty I, Kostner KM, Claudel T, et al. Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. J Lipid Res. 2012;53(11):2405\u201312. https:\/\/doi.org\/10.1194\/jlr.M029769.","journal-title":"J Lipid Res"},{"key":"2600_CR247","doi-asserted-by":"publisher","unstructured":"Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005;258(2):94\u2013114. https:\/\/doi.org\/10.1111\/j.1365-2796.2005.01528.x","DOI":"10.1111\/j.1365-2796.2005.01528.x"},{"issue":"9","key":"2600_CR248","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1161\/ATVBAHA.115.305835","volume":"35","author":"M Croyal","year":"2015","unstructured":"Croyal M, Ouguerram K, Passard M, et al. Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients. Arterioscler Thromb Vasc Biol. 2015;35(9):2042\u20137. https:\/\/doi.org\/10.1161\/ATVBAHA.115.305835.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2600_CR249","doi-asserted-by":"publisher","unstructured":"Schandelmaier S, Briel M, Saccilotto R, et al. Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev. 2017;6(6):CD009744. Published 2017 Jun 14. https:\/\/doi.org\/10.1002\/14651858.CD009744.pub2","DOI":"10.1002\/14651858.CD009744.pub2"},{"key":"2600_CR250","doi-asserted-by":"publisher","unstructured":"Fernandez-Prado R, Perez-Gomez MV, Ortiz A. Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease. Clin Kidney J. 2020;13(5):753\u2013757. Published 2020 Feb 11. https:\/\/doi.org\/10.1093\/ckj\/sfaa001","DOI":"10.1093\/ckj\/sfaa001"},{"issue":"21","key":"2600_CR251","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2004861","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Xia S. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. Reply N Engl J Med. 2020;382(21): e65. https:\/\/doi.org\/10.1056\/NEJMc2004861.","journal-title":"Reply N Engl J Med"},{"issue":"10057","key":"2600_CR252","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388(10057):2239\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(16)31009-1.","journal-title":"Lancet"},{"issue":"1","key":"2600_CR253","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41569-022-00813-7","volume":"20","author":"I Fern\u00e1ndez-Ruiz","year":"2023","unstructured":"Fern\u00e1ndez-Ruiz I. siRNA therapy markedly reduces Lp(a) levels. Nat Rev Cardiol. 2023;20(1):5. https:\/\/doi.org\/10.1038\/s41569-022-00813-7.","journal-title":"Nat Rev Cardiol"},{"key":"2600_CR254","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.atherosclerosis.2022.03.029","volume":"349","author":"DA Rider","year":"2022","unstructured":"Rider DA, Eisermann M, L\u00f6ffler K, et al. Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease. Atherosclerosis. 2022;349:240\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.03.029.","journal-title":"Atherosclerosis"},{"key":"2600_CR255","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2023.01.010","volume":"368","author":"S Stankov","year":"2023","unstructured":"Stankov S, Cuchel M. Gene editing for dyslipidemias: New tools to \u201ccut\u201d lipids. Atherosclerosis. 2023;368:14\u201324. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.01.010.","journal-title":"Atherosclerosis"},{"issue":"3","key":"2600_CR256","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11883-024-01187-6","volume":"26","author":"F Kronenberg","year":"2024","unstructured":"Kronenberg F. Lipoprotein(a): from Causality to Treatment. Curr Atheroscler Rep. 2024;26(3):75\u201382. https:\/\/doi.org\/10.1007\/s11883-024-01187-6.","journal-title":"Curr Atheroscler Rep"},{"key":"2600_CR257","doi-asserted-by":"publisher","unstructured":"Sosnowska B, Surma S, Banach M. Targeted Treatment against Lipoprotein (a): The Coming Breakthrough in Lipid Lowering Therapy. Pharmaceuticals (Basel). 2022;15(12):1573. Published 2022 Dec 16. https:\/\/doi.org\/10.3390\/ph15121573","DOI":"10.3390\/ph15121573"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02600-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02600-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02600-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T05:06:26Z","timestamp":1748063186000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-025-02600-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":257,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2600"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02600-y","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"186"}}